Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
RG3
Also known as: Retro-inverso peptide RG3, RG-3
RG3 is a retro-inverso peptide designed for antifibrotic and tissue-remodeling applications. Retro-inverso peptides use D-amino acids in reversed sequence to mimic the side-chain topology of the parent L-peptide while resisting proteolytic degradation. RG3 has been investigated in preclinical models for fibrotic conditions. Human evidence is essentially absent.
Risk Level
Medium RiskDifficulty
Advanced| Class | Peptide |
| Category | Underground Peptides |
Mechanism of Action
The retro-inverso design provides protease resistance while maintaining receptor binding capability. Proposed to modulate TGF-beta signaling pathways involved in fibrosis, reducing collagen deposition and extracellular matrix accumulation. Exact molecular target and binding specificity are not well characterized in published literature.
Dosing Research
No established human dosing. Underground use is extremely rare and dosing information is anecdotal. The retro-inverso design provides improved stability compared to conventional peptides, potentially allowing for less frequent dosing.
Side Effects & Risks
No human safety data. The use of D-amino acids may produce unpredictable immunogenic responses. Anti-fibrotic agents carry theoretical risks of impaired wound healing. This compound should be considered highly experimental with an uncharacterized risk profile.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.